Abstract

GENOMICS,GENETICSANDEPIGENETICSRESEARCHPROGRAM PROGRAMCODE:GGE PROJECTSUMMARY/ABSTRACT TheGenomics,GeneticsandEpigenetics(GGE)program(formerlytheCancerGeneticsandGenomics Program)consistsof48memberswhobelongto15differentacademicdepartmentsandareboundtogether bysharedinterestinstudyingthecancergenomeandepigenomeandtranslatingthisknowledgeintonew drugs,noveltherapeuticstrategies,andnoveldiagnostictests.Theprogramadoptedanewnamein2015by including?epigenetics?intheprogramtitletoreflectincreasinginterestbyitsmembersinepigeneticresearch. Theprogramhasthreemajorresearchthemes:1)identifyandcharacterizegeneticandepigeneticchanges thatdrivecancerformationandprogression;?2)developnewanalyticaltools,dataresources,andnovel laboratorymodelsthatenablegeneticallydriventherapeuticapproachesanddiagnostictests;?and3)translate thegenomicandgenetic/epigeneticdiscoveriesintonoveldrugsandnewdiagnostictests.Thesegoalsare accomplishedthroughprogrammaticinteractionbetweenlaboratoryscientists,clinicians/clinicaltrialists,and computationalbiologists.ThemostimportantfunctionoftheGGEprogramistofostercollaborations,guide recruitment,andprovidetechnologytoaccomplishthesegoals.Weorganizemonthlyresearchseminarsin whichmemberspresenttheirresearchprojectstodisseminateinformationacrosstheprogram.Wehold retreats/symposiaonrelevantcancergeneticstopicsandprogramleadersactivelyworkoncollaborative ?matchmaking?tobringtogethernewresearchteams,includingbasicandclinicalresearchers,toadvance cancerresearch.Throughthesemechanisms,sinceourlastrenewal,wehaverecruited19newmembersand increasedourtotalmembershipfrom44in2012to48in2017.Wealsocreatedseveralnewmultidisciplinary researchteams,establishedseveralnewinvestigator-initiatedclinicaltrialsledbyGGEmembers,and increasedcollaborationbothwithintheprogramandbetweenYCCprograms.Wealsoincreasedourtotal fundingbase.InJune2017,thetotalresearchfundingoftheprogramwas$11.5M,whichisa40% increasecomparedto$8.2M(alldirectcosts)atthetimeofthelastCCSGrenewalin2012.Totalpeer- reviewedfundingis$8.6M,ofwhich$1.9M(directcosts)comefromNCI.GGEmemberspublished718 cancer-relatedpapersbetweenJuly2012andJune2017,ofwhich17%wereintra-programmatic,30%inter- programmaticand66%collaborativepublicationswithinvestigatorsfromotherinstitutions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-39
Application #
9570291
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code

  Publications

Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications